Opinion|Videos|June 26, 2024
Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.
Advertisement
Episodes in this series
- Dr. Efstathiou asks Dr. Freedland: What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?
- What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (
Logan Cancers 2023 ,Kumaraswamy JCI Insight 2023 , please highlight any others)
Advertisement
Related to this article
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
China's NMPA Approves Pirtobrutinib Across CLL
5